PALISADE BIO, INC. Increase (Decrease) in Unbilled Receivables
PALISADE BIO, INC. (PALI) reported Increase (Decrease) in Unbilled Receivables of $234.38 thousand for the 12-month period ending 2011-12-31, per its 10-K filed 2012-03-30.
Discontinued › Notes
us-gaap:IncreaseDecreaseInUnbilledReceivables · last filed 2012-03-30
- PALISADE BIO, INC. increase (decrease) in unbilled receivables for fiscal 2011 was $234.38K.
| Period end | Increase (Decrease) in Unbilled Receivables 12 month |
|---|---|
| 2011-12-31 | $234.38K 10-K · filed 2012-03-30 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Lexeo Therapeutics, Inc. (LXEO) | United States | $0.278B | -4.19 |
| FATE THERAPEUTICS INC (FATE) | United States | $0.280B | -2.51 |
| Invivyd, Inc. (IVVD) | United States | $0.270B | -2.42 |
| Liminatus Pharma, Inc. (LIMN) | United States | $0.282B | |
| SUTRO BIOPHARMA, INC. (STRO) | United States | $0.260B | -3.05 |
| Inhibikase Therapeutics, Inc. (IKT) | United States | $0.296B | -4.44 |
| X4 Pharmaceuticals, Inc (XFOR) | United States | $0.297B | -4.99 |
| SAB Biotherapeutics, Inc. (SABS) | United States | $0.306B | -25.49 |
| Century Therapeutics, Inc. (IPSC) | United States | $0.306B | -4.02 |
| Lineage Cell Therapeutics, Inc. (LCTX) | United States | $0.241B | -10.35 |